Compare Incyte Corporation (INCY) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Yum! Brands, Inc. — how do they compare? Incyte Corporation trades at $118.02 (market cap $23.11B), while Yum! Brands, Inc. trades at $145.57 (market cap $40.62B). The key difference: Yum! Brands, Inc. is the larger of the two by market cap, and Yum! Brands, Inc. pays a 2.04% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | YUM | |
|---|---|---|
Market Cap | $23.11B | $40.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $168.16 |
52-Week Low | $67.38 | $138.21 |
Enterprise Value | $19.13B | $51.88B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
YUM trades at $147.44, down 0.32% amid bearish technical signals and negative news flow from a Taco Bell lettuce contamination outbreak. Fundamentally, the company shows revenue growth to $8.21B in 2025 with strong net income margins of 20.48%, though valuation ratios like P/E of 23.86 appear elevated. Recent earnings have been mixed with Q1 2026 beating expectations but Q4 2025 missing estimates.
The stock faces near-term headwinds from the food safety crisis but maintains analyst support with a $177 consensus target representing 20% upside. Long-term growth prospects remain intact with digital expansion and brand strength, though high debt levels and competitive pressures present ongoing risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
